Q1 FY27 results analysis · August 07, 2026

Sai Life Sciences Ltd (SAILIFE) Q1 FY27 Results Analysis: PAT Jumps 21%, Finance Costs Plunge 38%

+21.2%PAT year on year, Rs. 73.28 Cr
Cofacto ResearchPublished August 07, 20262 min readNegative read
Quick summary

Sai Life Sciences Ltd's Q1 FY27 numbers came in soft, with revenue of Rs. 554.29 Cr (+11.66% YoY) and PAT growth of +21.22% YoY. Here's a quick read of what worked, what to watch, and what management said.

Quick Details
Results dateAugust 06, 2026
QuarterQ1 FY 2026-2027
Revenue (Q1)Rs. 554.29 Cr (+11.66% YoY)
PAT (Q1)Rs. 73.28 Cr (+21.22% YoY)
EBITDA margin26.70% (+234 bps YoY)
EPS (Q1)Rs. 3.46 (+19.31% YoY)
Market capRs. 30,007.89 Cr
CMPRs. 1,413.50

Quarter Snapshot

Revenue grew 11.66% YoY but missed management's 15-20% CAGR guidance; EBITDA margin at 26.70% was also below the 28-30% target. PAT grew 21.22% YoY and finance costs declined 38% on debt repayment, but lumpy revenue and QoQ margin compression remain challenges. Capacity expansion catalysts are pending.

Key Investment Insights

Key Positives

  • Revenue grew 11.66% YoY to Rs.554.29 Cr.
  • EBITDA margin expanded 234 bps YoY to 26.70%.
  • PAT grew 21.22% YoY to Rs.73.28 Cr.
  • Finance costs declined 38.22% YoY to Rs.7.64 Cr due to debt repayment.
  • EBITDA growth (22.39% YoY) outpaced revenue growth (11.66% YoY).
  • No exceptional items in Q1FY27; normalized PAT equals reported PAT.

Risk Factors

  • Revenue growth of 11.66% YoY is below management's 15-20% CAGR guidance corridor.
  • EBITDA margin of 26.70% is below the sustained target band of 28-30%.
  • Sequential revenue declined 7.95% QoQ, confirming lumpy revenue pattern.
  • QoQ EBITDA margin compressed 262 bps, driven by employee cost share rising 146 bps QoQ.

Ask about this

Ask Cofacto a question about this result. Answers cite filings and company data.

Companies on this page

Related

Share on X · LinkedIn · WhatsApp

Disclaimer: This results analysis is published for educational and informational purposes only. It is not investment advice, not a recommendation to buy, sell or hold any security.